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Dendritic and lymphoid ‘exosomes’ regulate immune activation. Tumours release membranous material mimicking these ‘exosomes,’
resulting in deletion of reactive lymphocytes. Tumour-derived ‘exosomes’ have recently been explored as vaccines, without analysis
of their immunologic consequences. This investigation examines the composition of tumour-derived ‘exosomes’ and their effects on
T lymphocytes. Membranous materials were isolated from ascites of ovarian cancer patients (n¼6) and Western immunoblotting
was performed for markers associated with ‘exosomes.’ Using cultured T cells, ‘exosomes’ were evaluated for suppression of CD3-z
and JAK 3 expressions and induction of apoptosis, measured by DNA fragmentation. ‘Exosome’ components mediating suppression
of CD3-z were isolated by continuous eluting electrophoresis and examined by Western immunoblotting. ‘Exosomes’ were shown
to be identical with previously characterised shed membrane vesicles by protein staining and TSG101 expression. ‘Exosomes’
expressed class I MHC, placental alkaline phosphatase, B23/nucleophosmin, and FasL. ‘Exosomes’ suppressed expression of T-cell
activation signalling components, CD3-z and JAK 3 and induced apoptosis. CD3-z suppression was mediated by two components: 26
and 42kDa. Only the 42kDa component reacted with anti-FasL antibody. These results indicate that, while ‘exosomes’ express
tumour antigens, leading to their proposed utility as tumour vaccines, they also can suppress T-cell signalling molecules and induce
apoptosis.
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One general characteristic of tumours is their ability to release or
shed intact, vesicular portions of membrane material (termed
membrane fragments, membrane vesicles, microvesicles or exo-
somes), which was initially described by us, 25 years ago (Taylor
and Doellgast, 1979; Taylor et al, 1980). Recently, these tumour-
derived vesicles, or ‘exosomes,’ have gained attention as a source
of tumour antigens for vaccines, either directly or as part of
processed dendritic cells or dendritic cell-derived vesicles (Andre ´
et al, 2002a,b; Chaput et al, 2003; Kim et al, 2004).
Membrane vesicle shedding and its accumulation appear to be
important features of the malignant transformation. Shed tumour-
derived membrane vesicles do not mirror the general composition
of the plasma membrane of the originating tumour cell, but
represent ‘micromaps,’ with enhanced expression of tumour
antigens (Taylor and Black, 1986, 1987; Taylor et al, 1988). While
the precise mechanism of shedding remains unclear, the release of
membrane vesicles has been demonstrated to be an energy-
requiring phenomenon of viable cells, modulated by extracellular
signals (Taylor et al, 1983a, 1988). The rate of shedding is
significantly increased in most neoplastic cells and occurs
continuously (Taylor and Black, 1986, 1987; Taylor et al, 1983a,
1988, 2002). In addition to cancer cells, the release of membrane
vesicles was also demonstrated to be associated with cells of
embryonic origin (such as the placenta) and activated lymphoid
cells (Taylor and Black, 1986, 1987; Heijnen et al, 1999; Denzer
et al, 2000). Although extracellular shedding of membrane-derived
vesicles occurs in other types of cells, under specific physiological
conditions, the accumulation of shed membrane vesicles from
non-neoplastic cells is rarely observed (Taylor and Black, 1986;
Taylor et al, 2002).
Since shed membrane vesicles exhibit molecules with biologic
activity (such as Fas ligand, mdr 1, CD44, and autoreactive tumour
antigens) (Taylor et al, 1983b, 1984, 1989, 1996, 2002), the ability of
these shed membrane vesicles to modulate lymphocyte and
monocyte functions have been analysed in several tumour models.
Membrane vesicles released by metastatic tumour cells suppressed
the expression of class II MHC antigens by monocyte/macrophages
in a dose-dependent manner, while similar vesicles from early
stage tumour cells did not (Taylor and Black, 1985; Poutsiaka et al,
1985a,b). The shed membrane vesicles were also shown to
suppress lymphocyte activation with phytohaemoglutinin, Con-
canavalin A, or antiCD3 (Taylor et al, 1988). These shed tumour-
derived membrane vesicles also inhibited the activation of
lymphocytes with interleukin-2 (Pelton et al, 1991). Our recent
findings have demonstrated that these membrane vesicles can also
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ssuppress the expression of CD3-z and subsequent activation
signalling, inhibiting proliferation and cytokine production
(Taylor et al, 2003).
We have theorised that these shed vesicles modulate lymphocyte
functions by mimicking ‘activation-induced cell death’ (AICD)
(Taylor and Black 1986; Martinez-Lorenzo et al, 1999). Lymphoid
cells appear to release membrane vesicles following activation and
these appear to play an essential role in immunoregulation,
preventing of excessive immune responses and the development of
autoimmunity (Green et al, 2003). It was postulated that
membrane shedding by tumour cells was a re-expression of the
fetal cell shedding and that both constituted pathways to
circumvent immunosurveillance (Gerc¸el-Taylor et al, 2002).
These shed membrane vesicles were rediscovered in the mid-
1980s and termed ‘exosomes’ (Pan et al, 1985; Johnstone et al,
1987). These ‘exosomes’ were postulated to be functional exten-
sions of antigen-presenting cells, stimulating immune responses
(The ´ry et al, 2002). The ´ry characterized the composition and
physical properties of this membranous material, demonstrating
the ability of the centrifugal isolation procedure differentiated
between exosomes and other vesicular structures and large protein
aggregates The ´ry et al (1999). While characterizations of
‘exosomes’ have been consistent with our previously described
shed tumour-derived membrane vesicles, in terms of size (60–
100nm in diameter) and general composition, the term, ‘exo-
somes,’ has separated its literature from the published immuno-
logic activities of tumour-derived membrane vesicles. In the
present study, we are attempting to bridge this gap, to definitively
show identity between ‘exosomes’ and membrane vesicles and to
establish that these shed ‘exosomes’ possess immunosuppressive
activity.
MATERIALS AND METHODS
Patient-derived materials
Ascites were obtained from women diagnosed with stage IIIc
papillary serous adenocarcinoma of the ovary (n¼6) in the
Gynecologic Oncology Clinic of the Department of Obstetrics and
Gynecology of the University of Louisville School of Medicine.
Blood samples were also obtained from normal female volunteers
(n¼8) from the Gynecology Clinic of the Department of Obstetrics
and Gynecology of the University of Louisville School of Medicine.
The University Human Studies Committee of the University of
Louisville approved this study and informed consent was obtained
from each patient. Blood samples were allowed to clot and then
were centrifuged at 400g for 10min to sediment cells and clot. The
serum was removed, aliquoted, and stored at  701C until analysis.
For all of the samples studied, the age of the nontumour-bearing
female volunteers was 57.274.1 years, compared to 59.475.3
years for women with ovarian cancer.
Isolation of tumour-derived membrane vesicles
Membrane vesicles were isolated from ascites by two separate
procedures and then compared. The first protocol was the two-step
chromatography/centrifugation procedure developed in our la-
boratory (Taylor and Doellgast, 1979; Taylor et al, 2002) and the
second was the density gradient centrifugation procedure de-
scribed for ‘exosome’ isolation (Raposo et al, 1996). In the first
chromatography procedure, 10ml of ascites was applied to a Bio-
Gel A50m column (2.5 45cm) equilibrated with PBS. Fractions
(5ml) were collected; the elution monitored by absorption at
280nm and the void volume peak, containing material greater than
50 million Daltons, was collected. In the centrifugation procedure,
ascites were successively centrifugated at 300g for 10min, 800g for
30min, 10000g for 30min and 100000g for 1h. The pellet was
then washed in PBS and floatation of membrane vesicles on a
discontinuous sucrose gradient was performed at 41C as previously
described (Raposo et al, 1996). Membrane vesicles from both
procedures were then centrifuged at 100000g for 1h at 41C. The
pelleted membrane vesicles were resuspended in PBS and the
quantity of protein was determined by the Bradford microassay
method (Bio-Rad Laboratories, Hercules, CA, USA), using BSA as a
standard.
To compare the distributions of proteins in membrane materials
isolated by these procedures, SDS–PAGE using a 8–15%
acrylamide gel (Laemmli, 1970) was performed, followed by silver
staining (Bio-Rad Laboratories, Hercules, CA, USA). The stained
gels were analysed by Kodak 1D Image Analysis software (Eastman
Kodak, Rochester, NY, USA).
Western immunoblots analyses of ‘exosomes’ protein
expression
Western immunoblotting was performed to analyse the presence of
specific proteins, including HLA-A, PLAP, TSG101, FasL, B23/
nucleophosmin. Proteins from each ‘exosomes’ preparation (35mg)
were applied per lane of a 4–20% SDS–PAGE gel. The proteins
were electrophoretically separated by the method of Laemmli
(1970) and analysed by Western immunoblot as previously
described (Brown et al, 1993), probing overnight at 41C with
either rabbit polyclonal anti-FasL (1mgml
 1, Calbiochem, San
Diego CA, USA), rabbit polyclonal anti-PLAP (1mgml
 1, Abcam,
Cambridge, MA, USA), mouse monoclonal anti-TSG101
(1mgml
 1, Abcam, Cambridge, MA, USA), rabbit polyclonal
anti-B23/nucleophosmin (1mgml
 1, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), or goat polyclonal anti-HLA-A (1mgml
 1,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) as the primary
antibodies and peroxidase-conjugated anti-rabbit, goat, or mouse
immunoglobulin as the secondary antibody. The bound immune
complexes were visualised by enhanced chemiluminescence (ECL,
Amersham Life Sciences, Arlington Heights, IL, USA) and
quantitated by densitometry (Un-Scan-it Software, Silk Scientific
Corp., Orem, UT, USA).
Expression of signalling proteins, TcR/CD3-f and JAK3
Jurkat E-61 cells, a human T-cell lymphoma, was obtained from
the American Type Culture Collection (Manassas, VA, USA). These
cells were utilised as an in vitro assay for lymphocyte modulation
by ascites-derived ‘exosomes.’ This T-cell line was grown in RPMI
1640 medium supplemented with 0.1mM nonessential amino acids,
1m M sodium pyruvate, 200mML -glutamate, 100mgml
 1 strepto-
mycin and 100IUml
 1 penicillin in a humidified 5% CO2 chamber
at 371C. Cell viability was evaluated by trypan blue exclusion. All
cultures utilized for this study were 495% viable.
For bioassay of CD3-z expression, viable Jurkat cells
(10
6cellsml
 1) were incubated in a medium supplemented with
400mgml
 1 isolated ‘exosomes’ for 48h and were compared with
unexposed Jurkat cells or Jurkat cells exposed to the analogous
gradient fractions from control sera. After 2 days, the cells were
centrifuged, the cell pellet washed and used for protein analysis. To
assess CD3-z protein, the cell pellet was lysed using 50mM HEPES,
pH 7.2, 150mM NaCl, 5mM EDTA, 1mM sodium orthovanadate,
2.5% Triton X-100, 200mgml
 1 trypsin/chymotrypsin inhibitor,
200mgml
 1 chymostatin and 2mM PMSF. The cell lysate was
assayed for protein by the BioRad protein assay (Bio-Rad
Laboratories, Hercules, CA, USA). The modulation of signalling
proteins was analysed by Western immunoblot using a 15% SDS–
PAGE gel, as described above with mouse monoclonal anti-CD3-z
and mouse anti-JAK 3 antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) as the primary antibodies. As an additional
loading control, blots were also probed using rabbit polyclonal
anti-b-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
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The induction of apoptosis was examined as DNA fragmentation
in T lymphocytes. Cultures of Jurkat cells (2 10
5cellsml
 1)
following no treatment, treatment with 400mgml
 1 membrane
vesicles, or treatment with analogous material from control serum
were removed from the flask after 24h. DNA was isolated and
electrophoresed as previously described (Gibb et al, 1997). After
electrophoresis, DNA bands were visualised by 0.5mgml
 1
ethidium bromide staining.
Isolation of ‘exosomes’-associated inhibitory components
Using a continuously eluting electrophoresis system (Bio-Rad
Laboratories, Hercules, CA, USA), the components of ‘exosomes’
mediating suppression of CD3-z were analysed. ‘Exosomes’ from
two cancer patients (500mg each) were applied to 12.5%
acrylamide preparative column gels and each gel was run at
100V. Fractions (1ml) were eluted from the bottom of the gel,
monitoring at 280nm. Proteins from aliquots (200ml) of each
protein-containing fraction were precipitated using a 2-D clean up
kit to remove SDS (Amersham Biosciences, Arlington Heights, IL,
USA). The precipitated protein was resuspended in PBS by
sonication and assayed for z suppression in Jurkat cells. The
fractions exhibiting z suppression were concentrated and analysed
by SDS–PAGE on a 12.5% gel and subsequently by Western
immunoblotting with anti-FasL antibody.
Statistical Analysis
Western blot analyses of TSG101, HLA, PLAP, B23, FasL, CD3-z,
JAK3 were performed at least twice. Densitometric quantitation of
bands on each gel was standardised to a control lane included on
that gel and compared by the Kruskal–Wallis test. In the
remainder of experimental data, all relative absorbance determina-
tions were performed at least twice and the mean 7 standard error
of the mean for each sample was calculated. Tests with Po0.05
were considered statistically significant. Statistical analysis was
performed using InStat (GraphPad, San Diego, CA, USA).
RESULTS
Comparison of membrane vesicles and exosomes from
ascites of ovarian cancer patients
Using ascites from ovarian cancer patients, membrane vesicles
isolated by size exclusion chromatography were compared with
‘exosomes’ isolated by density gradient centrifugation. After
standardising for protein content, the membrane materials were
electrophoretically separated and the protein composition was
compared (Figure 1). Based on general protein composition,
chromatographically isolated membrane vesicles appear to be
identical to centrifugally isolated ‘exosomes’ obtained from the
same ascites. Subsequent analysis of TSG101 (previously demon-
strated to be associated with exosomes) (Stoorvogel et al, 2002) on
these membrane vesicles also indicated that the membrane
materials isolated by both procedures produced identical results
(Figure 2).
Characterisation of antigens associated with membrane
vesicles
Western immunoblot analysis of centrifugally isolated ‘exosomes’
demonstrated the presence of class I histocompatibility antigens in
the ascites-derived membrane vesicles, confirming the expression
previously shown for tumour-derived ‘exosomes’ (Figure 3A). To
define the origin of these membrane vesicles, the ‘exosome’-
association of placental-type alkaline phosphatase (PLAP), a
plasma membrane enzyme linked with ovarian cancer, was also
assayed (Figure 3D). Recent analyses at the gene and protein levels
have demonstrated PLAP expression in germ cell tumours and
syncytiotrophoblasts and only rarely is the protein or message
observed in normal adult tissues (Shigenari et al, 1998; Goldsmith
et al, 2002). All ‘exosome’ isolates stained positive for PLAP,
indicating the probable tumour origin of these membrane
materials. Our previous work demonstrated the presence of
autoantibodies bound to membrane vesicles, which were reactive
with B23/nucleophosmin (Katsanis et al, 1998); this finding
suggested a translocation of this nuclear protein to the cell surface
for exposure to the immune system. ‘Exosomes’ from four out of
six patients were positive for the presence of B23 by Western
immunoblots (Figure 3C). Since other investigators have suggested
the antitumour cellular immune response can be suppressed by the
presence of Fas ligand (FasL) (Rabinowich et al, 1998; Whiteside,
2002), shed ‘exosomes’ were assessed for expression of FasL. All
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Figure 1 SDS–PAGE separation of chromatographically isolated
membrane vesicles (designated lanes A) and centrifugally isolated
‘exosomes’ (designated lanes B) from the ascites of the same ovarian
cancer patients, visualised by silver staining.
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Figure 2 (A) Representative Western immunoblots of SDS–PAGE
separation of chromatographically isolated membrane vesicles (designated
lanes A) and centrifugally isolated ‘exosomes’ (designated lanes B) from the
ascites of the same ovarian cancer patients, incubated with anti-TSG101
antibody and visualised by ECL. (B) Densitometric analysis of TSG101
expression on these membrane vesicle isolates.
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ssamples were positive for the intact 41kDa form of FasL and two
were also strongly positive for the 27kDa cleaved form (Figure 3B).
Although control sera failed to exhibit shed membrane vesicles, the
analogous gradient fractions were analysed for the presence of
HLA, FasL, B23, and PLAP and were found to be negative (data not
shown).
Suppression of TcR/CD3-f and JAK 3 protein by shed
‘exosomes’
T lymphocytes from ovarian cancer patients have been demon-
strated to exhibit a loss of CD3-z expression and enhanced
apoptosis (Rabinowich et al, 1998; Whiteside, 2002). Our work has
suggested that JAK 3 may represent a common link between loss of
CD3-z protein and induction of apoptosis. Jurkat cells were
incubated for 2 days in medium containing 400mgml
 1 of
‘exosomes’ or the analogous gradient fraction from control sera,
and the expressions of CD3-z protein and JAK 3 were determined
by Western immunoblot. As shown in Figure 4, CD3-z and JAK 3
expressions were decreased in Jurkat cells incubated with
‘exosomes,’ compared to those incubated with analogous control
material.
‘Exosome’-mediated induction of apoptosis
Since it has been hypothesised that induction of T-cell apoptosis
by FasL is linked to the loss or decrease of TcR/CD3-z expression
(Rabinowich et al, 1998), the capability of FasL-expressing
‘exosomes’ to induce apoptosis was examined by assessing the
induction of DNA fragmentation (Figure 5). ‘Exosomes’ isolated
from ovarian cancer patients’ ascites induced significant apoptosis
compared to untreated Jurkat cells or Jurkat cells incubated with
the analogous control fraction.
‘Exosome’-associated inhibitory components
Since the preparations of ‘exosomes’ were observed to suppress
CD3-z and JAK 3 and to induce apoptosis within Jurkat cells, the
characteristics of the inhibitory component were evaluated.
‘Exosomes’ from two patients were electrophoretically separated
by continuously eluting electrophoresis. For each of the ‘exosome’
preparations, two separate fractions were identified. When these
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D
Figure 3 Western immunoblots demonstrating presence of HLA-A, Fas
ligand, B23/nucleophosmin, and placental alkaline phosphatase on cen-
trifugally isolated ‘exosomes’ from the ascites of ovarian cancer patients.
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Figure 4 (A) Western immunoblots indicating the expression of CD3-z
protein and JAK 3 by Jurkat cells, following incubation with 400mgml
 1 of
the centrifugally isolated ‘exosomes’ or analogous gradient material
(Control, C) for 48h. (B) Densitometric quantitation of CD3-z and JAK
3 expression by treated Jurkat cells.
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Figure 5 Induction of apoptosis in Jurkat T cells by 400mgml
 1 of the
centrifugally isolated ‘exosomes’ vs the analogous fraction from control
female controls for 24h, as defined by DNA fragmentation.
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PAGE gels, one component appeared at 26kDa and the second at
42kDa (Figure 6A). A separate preparation of this material was
analysed by Western immunoblotting with anti-FasL antibody,
since it has been implicated in suppression of CD3-z, induction of
T-cell apoptosis and exhibits molecular weight forms at these
molecular weights. Only the 41kDa component stained positive for
FasL (Figure 6B). Since our previous studies indicated that the
anti-FasL antibody used recognized both forms, the absence of
reactivity with the 26kDa components indicates that it is not FasL.
DISCUSSION
The shedding of membrane vesicles by tumour cells and their
subsequent appearance in blood specimens and malignant
effusions (ascites and pleural fluids) of cancer patients has been
recognised for over 25 years. These shed membrane vesicles have
been implicated in the immunosuppressive events associated with
advanced cancers. Owing to the presence of immunogenic tumour
antigens, early evidence suggested a role in the loss of surface
antigens by tumours and in competition for antibody binding
(Taylor et al, 1984, 1989; Katsanis et al, 1998; Gerc¸el-Taylor et al,
2001). Later, data demonstrated that as tumours progressed and
specific tumour subpopulations were selected or developed, these
shed membrane vesicles acquired the ability to suppress cellular
immunity (Taylor and Black, 1985, 1986; Pelton et al, 1991; Gerc¸el-
Taylor et al, 2002; Taylor et al, 2003). The acquisition of this
suppressive activity by membrane vesicles parallels the develop-
ment of anergy within these cancer patients.
In the 1980s, the release of ‘exosomes’ by lymphoid cells was
observed (Pan et al, 1985; Johnstone et al, 1987; The ´ry et al, 2002;
Stoorvogel et al, 2002). These ‘exosomes’ appeared to play a central
role in communication between lymphocytes and dendritic cells,
mediating the development of cellular responses or suppressing
excessive activation, as in AICD. The phenomena of shedding
‘exosomes’ have also been demonstrated with other haematopoie-
tic cells, such as mast cells and platelets, and it is thought to play
important roles mediating their actions (Raposo et al, 1997).
Recent studies have isolated ‘exosomes’ from tumour cells in vivo
and in vitro and have demonstrated the presence of tumour-
associated antigens and class I MHC antigens (Wolfers et al, 2001;
Andre ´ et al, 2002a,b; Chaput et al, 2004). These studies have
suggested that these tumour-derived ‘exosomes’ can serve as direct
vaccines or can be processed by autologous dendritic cells, which
can then be used to stimulate the anti-tumour response.
Our findings, as well as those of other investigators, have
demonstrated that membrane vesicles isolated from ovarian cancer
patients’ peripheral blood and malignant effusions appear to be
identical, in terms of general protein composition and presence of
specific marker proteins (Taylor et al 1980, 2002, 2003; Graves et al,
2004). However, to date, it is unclear whether the shed tumour-
derived membrane vesicles are the same or distinct from tumour-
derived ‘exosomes.’ Using our published chromatographic proce-
dure for membrane vesicle isolation and the published density
gradient centrifugation protocol for ‘exosomes’ purification, shed
membrane materials were isolated from ascites of ovarian cancer
patients. Based on protein staining, there are no significant
differences between the composition of these two preparations
(Figure 1). Further analysis of a marker, TSG101, previously
demonstrated to be associated with ‘exosomes,’ also demonstrated
no significant differences between chromatographically and
centrifugally isolated membrane materials (Figure 2).
Since ‘exosomes’ have been shown to exhibit HLA antigens and
tumour-associated antigens, the presence of specific antigens was
confirmed on ascites-derived ‘exosomes.’ These ‘exosome’ isolates
expressed HLA-A antigens at similar levels (Figure 3A), as well as
expressing two tumour-associated antigens (PLAP and B23)
(Taylor et al, 1984; Gerc¸el-Taylor et al, 2001) that have previously
been demonstrated to be present on membrane vesicles isolated
from both peripheral blood and ascites (Taylor et al, 1980, 2002,
2003) and to generate humoral responses in autologous patients
(Figure 3C and D). We further demonstrated that these shed
tumour-derived ‘exosomes’ expressed primarily the proapoptotic,
intact 41kDa FasL (Figure 3B).
Whiteside (2002) has proposed a link between T-cell apoptosis
and decreased CD3-z expression. Her work previously demon-
strated that coincubation of T lymphocytes with FasL-expressing
ovarian tumour cells resulted in both loss of CD3-z and induction
of lymphocyte apoptosis (Rabinowich et al, 1998). The expression
and release of FasL also appears to play a critical role of AICD of
peripheral T cells and the nonlymphoid FasL expression con-
tributes to peripheral lymphocyte deletion via apoptosis (Green
et al, 2003). This study addressed the consequences of ‘exosome’
expression of biologically active molecules, such as FasL. When
ascites-derived ‘exosomes’ were incubated with T cells (Jurkat
cells) for 48h, suppression of both CD3-z and JAK 3 proteins were
observed (Figure 4). This suppression was observed using
400mgml
 1 of membrane proteins. Our previous work demon-
strated that this membrane material was present at a level of
2.0670.73mgml
 1 in advanced ovarian cancer patients. These
FasL-containing ‘exosomes’ were further analysed for their ability
to induce apoptosis (Figure 5). Induction of significant DNA
CP3
CP3
fr A fr A
CP5 CP3
fr B fr B
std fr A fr A fr B fr B
CP5
CP5
25 kDa
36 kDa
42 kDa
25 kDa
36 kDa
42 kDa
A
B
Figure 6 Identification of the ‘exosomes’-associated inhibitors of CD3-z
expression. ‘Exosomes’ were fractionated by continuously eluting electro-
phoresis and fractions were subsequently assayed for z suppression in a
Jurkat bioassay. The fractions suppressing z expression were examined by
SDS–PAGE with silver staining (A). Western immunoblotting of the two
fractions with anti-FasL demonstrated reactivity with the 42kDa compo-
nent, but not with the 26kDa (B).
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Fractionation of ‘exosomes’ revealed two distinct fractions
mediating suppression of CD3-z (Figure 6A): 26 and 42kDa.
Western immunoblotting demonstrated the 42kDa component to
be FasL, while the 26kDa component did not react with anti-FasL.
Current studies are focused on sequencing the 26kDa component.
Our analyses of tumour-derived ‘exosomes’ have confirmed
their identity with shed membrane vesicles; however, the use of the
term ‘exosomes’ has caused a failure to link them with their
published immunologic consequences. Since shed tumour mem-
brane vesicles or ‘exosomes’ do possess tumour-derived antigens
that can elicit autologous immunologic responses, the potential use
of these proteins as targets for vaccines is promising; however,
these antigenic components need to be separated from those
components mediating suppression of T-cell signalling and
inducing apoptosis. Based on their known immunosuppressive
characteristics, their potential use intact as vaccines should be
performed with caution.
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